Scilex Holding (SCLX) Current Deferred Revenue (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Current Deferred Revenue of $398000.0 for Q1 2026, down 8.92% year-over-year from $437000.0 in Q1 2025, and down 2.21% on a QoQ basis from $407000.0 in Q4 2025.
Scilex Holding (SCLX) Current Deferred Revenue (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Current Deferred Revenue for 5 consecutive years, with $398000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 8.92% year-over-year to $398000.0; the TTM figure through Mar 2026 stood at $398000.0 (down 8.92% YoY), while the FY2025 annual figure was $407000.0, down 8.95% from the prior year.
- Current Deferred Revenue came in at $398000.0 for Q1 2026 at Scilex Holding, down from $407000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $516000.0 in Q2 2023, with the low at $264000.0 in Q4 2022.
- Average Current Deferred Revenue over 5 years is $436071.4, with a median of $442000.0 recorded in 2024.
- Across the five-year window, Current Deferred Revenue surged 85.98% in 2023 and dropped 9.11% in 2024, its largest moves.
- Year by year, Current Deferred Revenue stood at $264000.0 in 2022, then soared by 85.98% to $491000.0 in 2023, then decreased by 8.96% to $447000.0 in 2024, then slipped by 8.95% to $407000.0 in 2025, then decreased by 2.21% to $398000.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $398000.0, $407000.0, and $417000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 398,000.00 |
| Dec 31, 2025 | 407,000.00 |
| Sep 30, 2025 | 417,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 437,000.00 |
| Dec 31, 2024 | 447,000.00 |
| Sep 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 469,000.00 |
| Mar 31, 2024 | 480,000.00 |
| Dec 31, 2023 | 491,000.00 |
| Sep 30, 2023 | 503,000.00 |
| Jun 30, 2023 | 516,000.00 |
| Mar 31, 2023 | 391,000.00 |
| Dec 31, 2022 | 264,000.00 |